Results 201 to 210 of about 49,721 (234)
Some of the next articles are maybe not open access.
Bulletin du cancer, 2015
Paclitaxel is conventionally used in a wide range of oncology indications. Nab-paclitaxel is synthesized by a process of high pressure homogenization of paclitaxel in the presence of human albumin and it was originally developed to reduce the toxicity usually associated with cremophor in soluble paclitaxel and to increase its penetration in tumor ...
Daniel, Lopez-Trabada Ataz +2 more
openaire +1 more source
Paclitaxel is conventionally used in a wide range of oncology indications. Nab-paclitaxel is synthesized by a process of high pressure homogenization of paclitaxel in the presence of human albumin and it was originally developed to reduce the toxicity usually associated with cremophor in soluble paclitaxel and to increase its penetration in tumor ...
Daniel, Lopez-Trabada Ataz +2 more
openaire +1 more source
Gemcitabine/nab‐paclitaxel for pediatric relapsed/refractory sarcomas
Pediatric Blood & Cancer, 2018AbstractBackgroundPediatric patients with relapsed/refractory sarcomas have poor outcomes and need novel therapies that provide disease control while maintaining an acceptable quality of life. The activity and toxicity of gemcitabine and nab‐paclitaxel in combination has not been reported in pediatrics.ProcedureWe reviewed the records of fifteen ...
Jonathan L. Metts +7 more
openaire +2 more sources
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
The Kobe journal of medical sciences, 2017Albumin-bound paclitaxel (Abraxane®, nab-paclitaxel) is not recommended to be administered concurrently or sequentially with other drugs due to concern for instability. The need to administer drugs separately increases infusion time. We evaluated the compatibility and stability of solutions containing nab-paclitaxel and other drugs, including ...
Mizuta, Naomi +8 more
openaire +2 more sources
nab-Paclitaxel for the Treatment of Aggressive Metastatic Breast Cancer
Clinical Breast Cancer, 2014Despite advances in early diagnosis, prevention, and treatment, breast cancer remains the second-leading cause of cancer-related deaths in women. The 5-year survival rate for patients with metastatic breast cancer (MBC) is just 24%. However, some forms of MBC appear to be more aggressive than others.
openaire +2 more sources
Gemcitabine and nab-paclitaxel induced interstitial pneumonia
Diagnostic and Interventional Imaging, 2021Claire Sabat +2 more
openaire +2 more sources
Reminder that paclitaxel and nab-paclitaxel not interchangeable
Reactions Weekly, 2022openaire +1 more source